Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 4/20 | 0.41 |
| ▸ | GSK3B | P49841 | 4/20 | 0.41 |
| ▸ | PIM1 | P11309 | 3/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.41 |
| ▸ | CLK2 | P49760 | 2/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.41 |
| ▸ | MET | P08581 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 2/20 | 0.41 |
| ▸ | PAK4 | O96013 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.41 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8531 | 0.89 | METAP2 (0.40) | DYRK1AFGFR1NOS1MAPTMETAP2 | |
| SCHEMBL15778365 | 0.80 | PIK3C3 (0.33) | — | |
| SCHEMBL8622 | 0.78 | ENPP2 (0.41) | MAPTRAB9AGAAMAOBNPC1 | |
| SCHEMBL2350927 | 0.77 | AXL (0.42) | MAPTRAB9AKDM4EMEN1ALDH1A1 | |
| SCHEMBL18189751 | 0.75 | — | — | |
| SCHEMBL29636278 | 0.74 | ROCK2 (0.53) | ROCK1GSK3BPIM1AURKBCLK2 | |
| SCHEMBL481818 | 0.74 | ROCK2 (0.53) | ROCK1GSK3BPIM1AURKBCLK2 | |
| SCHEMBL517925 | 0.74 | CA1 (0.50) | CDK5KDM4EALDH1A1TDP1CDK5R1 | |
| SCHEMBL2361665 | 0.73 | MMP12 (0.34) | MAPTKDM4EALDH1A1TDP1 | |
| Hydrochloric Acid SCHEMBL29957203 | 0.73 | ROCK2 (0.52) | ROCK1GSK3BPIM1AURKBCLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360095-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS AG (CH) | 2024-10-31 | — | — | US | disclosed |
| EP-3825322-B1 | POLYPEPTIDE COMPOUND, PHARMACEUTICAL COMPOSITION, PREPARATION METHOD AND APPLICATION THEREOF | CHENGDU SINTANOVO BIOTECHNOLOGY CO LTD (CN) | 2024-03-20 | — | — | EP | disclosed |
| CN-114072387-B | Indazole compound, pharmaceutical composition and application thereof | 暨南大学 | 2024-03-08 | — | — | CN | disclosed |
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | disclosed |
| US-11643436-B2 | Polypeptide compound, pharmaceutical composition, preparation method and application thereof | CHENGDU SINTANOVO BIOTECHNOLOGY CO., LTD. (CN) | 2023-05-09 | — | — | US | disclosed |
| EP-4056558-A1 | INDAZOLE COMPOUND, PHARMACEUTICAL COMPOSITION OF SAME, AND APPLICATIONS THEREOF | Jinan University (CN) | 2022-09-14 | — | — | EP | disclosed |
| US-20220281821-A1 | INDAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL COMPOSITIONS | JINAN UNIVERSITY (CN) | 2022-09-08 | — | — | US | disclosed |
| US-11352360-B2 | TGF-beta inhibitors | Rigel Pharmaceuticals, hic. (US) | 2022-06-07 | — | — | US | disclosed |
| CN-114072387-A | Indazole compound and medicinal composition and application thereof | 暨南大学 | 2022-02-18 | — | — | CN | disclosed |
| CN-108026110-B | Fused tricyclic compounds as protein kinase inhibitors | 国家公共部门基金会卡洛斯三世国家癌症研究中心(F.S.P.CNIO) | 2022-02-08 | — | — | CN | disclosed |
| EP-2588471-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | Amgen Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-04-11 | — | — | US | disclosed |
| EP-2496567-A2 | NOVEL BENZOPYRAN KINASE MODULATORS | Rhizen Pharmaceuticals S.A. (CH) | 2012-09-12 | — | — | EP | disclosed |
| US-20120059001-A1 | NOVEL KINASE MODULATORS | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2012-03-08 | — | — | US | disclosed |
| WO-2012003283-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| WO-2011101640-A1 | FUSED HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF MALARIA | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2011-08-25 | — | — | WO | disclosed |
| US-20110118257-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS SA (CH) | 2011-05-19 | — | — | US | disclosed |
| WO-2011055215-A2 | NOVEL KINASE MODULATORS | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2011-05-12 | — | — | WO | disclosed |
| WO-2010010186-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2010-01-28 | — | — | WO | disclosed |
| WO-2010010184-A1 | [1, 2, 4] TRIAZOLO [1, 5-A] PYRIDINES AS JAK INHIBITORS | GALAPAGOS NV (BE) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352360-B2 | TGF-beta inhibitors | TGFBR1, TGFBR2, TGFB1 | ROCK1 140/4885GSK3B 33/4885PIM1 1264/4885 |
| US-20240360095-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | ROCK1 477/4885GSK3B 255/4885PIM1 735/4885 |
| US-11643436-B2 | Polypeptide compound, pharmaceutical composition, preparation method and application thereof | OPRL1, OPRK1, OPRM1 | ROCK1 3946/4885GSK3B 1482/4885PIM1 3981/4885 |
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | ROCK1 714/4885GSK3B 716/4885PIM1 337/4885 |
| US-20110118257-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | ROCK1 477/4885GSK3B 255/4885PIM1 735/4885 |
| US-20220281821-A1 | INDAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL COMPOSITIONS | TNK2, TNNI3K, CSNK1G3 | ROCK1 296/4885GSK3B 34/4885PIM1 335/4885 |
| US-11858907-B2 | Kinase modulators | RPS6KA1, RPS6KA2, PRKAR2A | ROCK1 106/4885GSK3B 285/4885PIM1 802/4885 |
| US-20120059001-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | ROCK1 477/4885GSK3B 255/4885PIM1 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.